PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Classifica tra le azioni #1423
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Prezzo delle azioni
$37.84
Capitalizzazione di mercato
$15.65B
Variazione (1 giorno)
-4.42%
Variazione (1 anno)
149.23%
Paese
TW
Scambia PharmaEssentia Corporation (6446)

Categoria

Healthcare
EPS per PharmaEssentia Corporation (6446)
EPS al June 2026 TTM: $0.63
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di PharmaEssentia Corporation, l’EPS attuale della società (TTM) è $0.63. Alla fine del 2023, la società aveva un EPS di $-0.06 una diminuzione rispetto a rispetto a quello del 2022, che era di $-0.14.
Storico EPS per PharmaEssentia Corporation da 2010 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
2026 (TTM) $0.63 153.00%
2024 $0.25 -534.22%
2023 $-0.06 -60.15%
2022 $-0.14 -59.50%
2021 $-0.35 37.91%
2020 $-0.25 119.47%
2019 $-0.12 -14.95%
2018 $-0.14 15.09%
2017 $-0.12 5.89%
2016 $-0.11 -6.67%
2015 $-0.12 -4.08%
2014 $-0.13 25.60%
2013 $-0.10 63.82%
2012 $-0.06 25.36%
2011 $-0.05 16.87%
2010 $-0.04 0.00%
EPS per aziende simili o concorrenti